Squarepoint
LTGO

Squarepoint’s Latigo Biotherapeutics LTGO Stock Holding History

Squarepoint’s Portfolio LTGO Stock Details LTGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$587K Buy
+35,145
New +$742K ﹤0.01% 3256

Other funds holding LTGO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jacobi Capital Management
Jacobi Capital Management Pittston, Pennsylvania $2.11B AUM 19.6% 1-Year Est. Return

Squarepoint's LTGO Position: Q3 2026 in Review

Squarepoint opened a new position in Latigo Biotherapeutics (LTGO) in Q3 2026: 35,145 shares worth $587K. The stake represents ﹤0.01% of the portfolio and ranks #3256 among its holdings.

9 funds tracked by Wall St. Rank hold LTGO as of Q3 2026.

  • Squarepoint held 35,145 shares of Latigo Biotherapeutics worth $587K as of Q3 2026.
  • Latigo Biotherapeutics was a new Squarepoint position in Q3 2026.
  • Latigo Biotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3256 holding.
  • 9 funds tracked by Wall St. Rank held Latigo Biotherapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.